Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Kits > Spike RBD > EP-109

SARS-CoV-2 (B.1.351) Inhibitor Screening Kit (Spike RBD)

For research use only.

Order Now

EP109-C01Pre-coated Human ACE2 Microplate1 plate
EP109-C02SARS-CoV-2 Inhibitor10 μg
EP109-C03HRP-SARS-CoV-2 Spike RBD(B.1.351)15 μg
EP109-C0410xWashing Buffer50 mL
EP109-C05Dilution Buffer50 mL
EP109-C06Substrate Solution12 mL
EP109-C07Stop Solution7 mL
  • Background
    Multiple variants of SARS-CoV-2 are circulating globally and posting new challenges to human health. As concerns over the potential impacts of the variants grow, the deleloped of effcient treatment agaginst multiple variants of SARS-CoV-2 is an emergent need for global pubic heath.It is necessary to develop SARS-CoV-2 inhibitors, such as vaccines,therapeutic antibodies and small molecule compounds against SARS-CoV-2(B.1.351).

    Therefore, it is helpful to develop the SARS-CoV-2 (B.1.351) Inhibitor Screening Kit (Spike RBD) to test SARS-CoV-2 inhibitors.

  • Application

    This kit is developed for screening inhibitors of SARS-CoV-2 (B.1.351).

    It is for research use only.

  • Reconstitution
    Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
  • Storage & Shipping
    1. Unopened kit should be stored at 2℃-8℃ upon receiving.

    2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.

    3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

    Shipping Statement

  • Assay Principles
    This assay kit is used to measure the levels of Anti-SARS-CoV-2 neutralizing antibody through a competitive ELISA. The microplate in the kit has been pre-coated with Human ACE2 protein. First samples are added to the wells followed by addition of HRP-SARS-CoV-2 Spike RBD. After incubation, the wells are washed and substrate is added to the wells. The reaction is terminated by the addition of stop solution and the intensity of color is measured at 450 nm. The presence of neutralizing antibodies in samples will compete with ACE2 for HRP-SARS-CoV-2 Spike RBD binding. The intensity of assay signal decrease proportionally to the presence of Anti-SARS-CoV-2 neutralizing antibody.

    Your experiment will include 5 simple steps:

    a) All reagents were returned to room temperature(20°C-25°C) before use.

    b) Make series the tested sample and control with ditlution buffer, HRP-SARS-CoV-2 RBD diluted with dilution buffer.

    c) Add the diluted sample, Control and the HRP-SARS-CoV-2 RBD add the plate respectively.

    d) Wash the plate and add TMB or other colorimetric HRP substrate.

    e) Stop the substrate reaction by add diluted acid. Absorbance (OD) is calculated as the absorbance at 450 nm minus the absorbance at 630 nm to remove background prior to statistical analysis. The OD Value reflects the amount of antibody bound.

Typical Data Please refer to DS document for The assay protocol.

Incubation of SARS-CoV-2 inhibitor:Blocking the binding of HRP-SARS-CoV-2 Spike RBD(B.1.351) to Human ACE2.
Serial dilutions of SARS-CoV-2 inhibitor (Catalog # EP109-C02) (1:1 serial dilutions, from 10.0ug/mL to 0.0195ug/mL(68.8nM to 0.13nM)) and loaded onto the plate coated by human ACE2 in the presence of HRP-SARS-CoV-2 Spike RBD(B.1.351).Background was subtracted from data points prior to log transformation and curve fitting (QC tested).

  • Clinical and Translational Updates

Comments (0)

Promotion & Exhibitions

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message